Malignant Transformation of Reese's Melanosis: A Case of Conjunctival Melanoma and Related Therapeutic Modalities.

Autor:	Kharmach I; Medical Oncology, Mohammed VI University Hospital, Oujda, MAR.; Medical Oncology, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR., Rezzoug F; Medical Oncology, Mohammed VI University Hospital, Oujda, MAR.; Medical Oncology, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR., Moukhlissi M; Radiotherapy, Mohammed VI University Hospital, Oujda, MAR.; Medical Oncology, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR., Al Jarroudi O; Medical Oncology, Mohammed VI University Hospital, Oujda, MAR.; Medical Oncology, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR., Brahmi SA; Medical Oncology, Mohammed VI University Hospital, Oujda, MAR.; Medical Oncology, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR., Afqir S; Medical Oncology, Mohammed VI University Hospital, Oujda, MAR.; Medical Oncology, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Jun 13; Vol. 16 (6), pp. e62331. Date of Electronic Publication: 2024 Jun 13 (Print Publication: 2024).
DOI:	10.7759/cureus.62331
Abstrakt:	Conjunctival melanoma is a rare but aggressive condition that can arise from healthy conjunctiva, pre-existing nevi, or precancerous conditions like Reese's melanosis. This acquired primary conjunctival melanosis can significantly impact an individual's quality of life due to its potential for recurrence and metastasis. Effective treatment typically requires a multidisciplinary approach to optimize outcomes. We present the case of a 56-year-old patient with recurrent Reese melanoma who underwent multiple surgeries. During the last intervention, a malignant transformation into melanoma was discovered. Due to the absence of brachytherapy facilities, the patient received local treatment with mitomycin C eye drops. Despite this limitation, the patient showed no signs of recurrence one year post-treatment. Given the high risk of local recurrence after surgery alone, additional radiotherapy is recommended and should be systematically discussed. Regular monitoring and timely intervention are essential to prevent disease progression. Notably, the frequent BRAF (B-Raf proto-oncogene, serine/threonine kinase) mutation in conjunctival melanoma opens possibilities for targeted therapies, such as BRAF inhibitors, offering promising options for management alongside traditional surgical approaches. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Kharmach et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu